These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38966689)

  • 1. Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment.
    Wademan DT; Draper HR; Purchase SE; Palmer M; Hesseling AC; Van der Laan L; Garcia-Prats AJ
    IJTLD Open; 2024 Feb; 1(2):69-75. PubMed ID: 38966689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paediatric formulations of artemisinin-based combination therapies for treating uncomplicated malaria in children.
    Bélard S; Ramharter M; Kurth F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD009568. PubMed ID: 33289099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children.
    van der Laan LE; Hesseling AC; Schaaf HS; Palmer M; Draper HR; Wiesner L; Denti P; Garcia-Prats AJ
    J Antimicrob Chemother; 2023 Oct; 78(10):2481-2488. PubMed ID: 37596982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects.
    Abdulla S; Amuri B; Kabanywanyi AM; Ubben D; Reynolds C; Pascoe S; Fitoussi S; Yeh CM; Nuortti M; Séchaud R; Kaiser G; Lefèvre G
    Malar J; 2010 Sep; 9():253. PubMed ID: 20815879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptability of Prednisolone in an Open-Label Randomised Cross-Over Study-Focus on Formulation in Children.
    Haslund-Krog SS; Jørgensen IM; Dalhoff K; Holst H
    Children (Basel); 2022 Aug; 9(8):. PubMed ID: 36010126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis.
    Purchase SE; Garcia-Prats AJ; De Koker P; Draper HR; Osman M; Seddon JA; Schaaf HS; Hesseling AC
    Pediatr Infect Dis J; 2019 Jun; 38(6):608-610. PubMed ID: 30550511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children.
    Abdulla S; Sagara I
    Malar J; 2009 Oct; 8 Suppl 1(Suppl 1):S7. PubMed ID: 19818174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial.
    Abdulla S; Sagara I; Borrmann S; D'Alessandro U; González R; Hamel M; Ogutu B; Mårtensson A; Lyimo J; Maiga H; Sasi P; Nahum A; Bassat Q; Juma E; Otieno L; Björkman A; Beck HP; Andriano K; Cousin M; Lefèvre G; Ubben D; Premji Z
    Lancet; 2008 Nov; 372(9652):1819-27. PubMed ID: 18926569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Holistic acceptability of an adult levofloxacin formulation in children and adolescents on a tuberculosis preventive treatment trial.
    Purchase SE; Wademan DT; Tshetu NL; Rafique M; Hoddinott G; Seddon JA; Schaaf HS; Hesseling AC
    PLOS Glob Public Health; 2024; 4(7):e0003381. PubMed ID: 38968182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-Processed Excipients for Dispersible Tablets-Part 2: Patient Acceptability.
    Dziemidowicz K; Lopez FL; Bowles BJ; Edwards AJ; Ernest TB; Orlu M; Tuleu C
    AAPS PharmSciTech; 2018 Aug; 19(6):2646-2657. PubMed ID: 29943280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical and psychosocial challenges faced by caregivers influence the acceptability of multidrug-resistant tuberculosis preventive therapy for young children.
    Wademan DT; Hoddinott G; Purchase SE; Seddon JA; Hesseling AC; Garcia-Prats AJ; Reis R; Reynolds LJ
    PLoS One; 2022; 17(7):e0268560. PubMed ID: 35834509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
    Singh RP; Shaik JSB; Skoura N; Joshi S; Shreeves T; Casillas L; Buchanan AM
    J Acquir Immune Defic Syndr; 2018 Dec; 79(5):631-638. PubMed ID: 30239425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.
    Garcia-Prats AJ; Purchase SE; Osman M; Draper HR; Schaaf HS; Wiesner L; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
    Ruel TD; Acosta EP; Liu JP; Gray KP; George K; Montañez N; Popson S; Buchanan AM; Bartlett M; Dayton D; Anthony P; Brothers C; Vavro C; Singh R; Koech L; Vhembo T; Mmbaga BT; Pinto JA; Dobbels EFM; Archary M; Chokephaibulkit K; Ounchanum P; Deville JG; Hazra R; Townley E; Wiznia A;
    Lancet HIV; 2022 May; 9(5):e332-e340. PubMed ID: 35489377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low- and High-Mineral-Content Water on the Tablet in Healthy Adults.
    Buchanan AM; Holton M; Conn I; Davies M; Choukour M; Wynne BR
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):577-583. PubMed ID: 28168828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative palatability of orally disintegrating tablets (ODTs) of Praziquantel (L-PZQ and Rac-PZQ) versus current PZQ tablet in African children: A randomized, single-blind, crossover study.
    Mahende MK; Huber E; Kourany-Lefoll E; Ali A; Hayward B; Bezuidenhout D; Bagchus W; Kabanywanyi AM
    PLoS Negl Trop Dis; 2021 Jun; 15(6):e0007370. PubMed ID: 34106922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey of caregivers of Nigerian children less than 6 years of age to determine the experience and perception of acceptability of oral solid dosage forms.
    Orubu S; Okwelogu C; Opanuga O; Tuleu C
    Int J Pharm; 2018 Feb; 536(2):582-589. PubMed ID: 29100913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.
    Kovarik JM; Noe A; Berthier S; McMahon L; Langholff WK; Marion AS; Hoyer PF; Ettenger R; Rordorf C
    J Clin Pharmacol; 2003 Feb; 43(2):141-7. PubMed ID: 12616666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children.
    Svensson EM; du Bois J; Kitshoff R; de Jager VR; Wiesner L; Norman J; Nachman S; Smith B; Diacon AH; Hesseling AC; Garcia-Prats AJ
    Br J Clin Pharmacol; 2018 Jun; 84(10):2384-92. PubMed ID: 29952141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
    Waalewijn H; Chan MK; Bollen PDJ; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Sarfati T; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Moore CL; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
    Lancet HIV; 2022 May; 9(5):e341-e352. PubMed ID: 35189082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.